A Study of Gentuximab in Combination With Almonertinib in EGFR Mutation-positive Metastatic NSCLC
Clinical trial NCT05223595 · UNKNOWN
Trial details
- NCT number
- NCT05223595
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-04-02
- Primary completion
- 2023-09-30
- Enrollment
- 42
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.